BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25855381)

  • 1. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
    Saito M; Shimada Y; Shiraishi K; Sakamoto H; Tsuta K; Totsuka H; Chiku S; Ichikawa H; Kato M; Watanabe S; Yoshida T; Yokota J; Kohno T
    Cancer Res; 2015 Jun; 75(11):2264-71. PubMed ID: 25855381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
    Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIF5B-RET fusions in lung adenocarcinoma.
    Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
    Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
    J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
    Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 19. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.